Fate Therapeutics makes two appointments, one promotion
This article was originally published in Scrip
Executive Summary
Fate Therapeutics, a biopharmaceutical company developing cellular therapeutics for the treatment of life-threatening diseases, has named Dr Wendy Levin vice-president of clinical development and Walter Grubb vice-president of business development. Dr Levin, a board-certified hematologist/oncologist, joins Fate from MEI Pharma, where she was vice-president of clinical development and medical affairs. Mr Grubb was previously executive director of business development and commercial operations at Ambit Biosciences.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.